Advertisement

Clinical Drug Investigation

, Volume 39, Issue 4, pp 407–410 | Cite as

Paliperidone Long-Acting Injections in Huntington’s Disease for Motor and Behavioural Disturbances

  • Nameer van OosteromEmail author
  • Theo Theodoros
Case Report

Abstract

Oral antipsychotics are used to treat motor and behavioural disturbances in Huntington’s disease (HD). However, patients with behavioural disturbances are often non-compliant, thus the oral route is inappropriate. The effects of antipsychotic long-acting injections (LAI) in HD are significantly underrepresented in literature. Paliperidone LAI (P-LAI), an atypical antipsychotic, has benefits over other antipsychotics LAI with its long dosing interval and no initial oral overlap, but has no documented cases for this indication. This case of a 45-year-old female highlights the use of P-LAI for severe aggression and chorea secondary to HD causing failed placement in assisted-care accommodation and mobility via an electronic-wheelchair. Three weeks after commencing treatment, she could walk unassisted, and displayed no aggression. After 10 months, she still had significant improvements and resided in the same accommodation for 6 months without any concern. Thus, this case suggests that P-LAI may be a treatment option for non-compliant HD patients.

Notes

Compliance with Ethical Standards

Funding

The authors declare that no source of funding was obtained for this research.

Conflicts of interest

Dr Theo Theodoros has attended educational events organised by Jannsen: Pharmaceutical Companies of Johnson & Johnson (where expenses were paid). Nameer van Oosterom has not conflict of interest to declare.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This study was also approved by the Metro South Human Research Ethics Committee (reference number: HREC/18/QPAH/87).

Informed consent

A waiver of consent was granted for this project by the Metro South Human Research Ethics Committee.

References

  1. 1.
    Burgunder J-M, Guttman M, Perlman S, Goodman N, van Kammen DP, Goodman L. An International survey-based algorithm for the pharmacologic treatment of chorea in Huntington’s Disease. PLoS Curr. 2011.  https://doi.org/10.1371/currents.rrn1260.Google Scholar
  2. 2.
    Duff K, Beglinger LJ, O’Rourke ME, Nopoulos P, Paulson HL, Paulsen JS. Risperidone and the treatment of psychiatric, motor, and cognitive symptoms in Huntington’s disease. Ann Clin Psychiatry. 2008;20(1):1–3.  https://doi.org/10.3109/10401230701844802.CrossRefGoogle Scholar
  3. 3.
    Johnston GT. Risperidone long-acting injection and Huntingtonʼs disease: case series with significant psychiatric and behavioural symptoms. Int Clin Psychopharmacol. 2011;26(2):114–9.  https://doi.org/10.1097/YIC.0b013e3283407775.CrossRefGoogle Scholar
  4. 4.
    Chen J, Wang E, Cepeda C, Levine M. Dopamine imbalance in Huntington’s disease: a mechanism for the lack of behavioral flexibility. Front Neurosci. 2013;7:7.  https://doi.org/10.3389/fnins.2013.00114.Google Scholar
  5. 5.
  6. 6.
    Corena-McLeod M. Comparative pharmacology of risperidone and paliperidone. Drugs R&D. 2015;15(2):163–74.  https://doi.org/10.1007/s40268-015-0092-x.CrossRefGoogle Scholar
  7. 7.
  8. 8.
    Galletly C, Castle D, Dark F, Humberstone V, Jablensky A, Killackey E, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Aust N Z J Psychiatry. 2016;50(5):410–72.  https://doi.org/10.1177/0004867416641195.CrossRefGoogle Scholar
  9. 9.
    Barnes TRE, Taylor DM, Young AH. The Maudsley prescribing guidelines in psychiatry. Newark: Wiley; 2018.Google Scholar
  10. 10.
    Jung HY, Kim JH, Ahn YM, Kim SC, Hwang SS, Kim YS. Liverpool university neuroleptic side-effect rating scale (LUNSERS) as a subjective measure of drug-induced parkinsonism and akathisia. Human Psychopharmacol Clin Exp. 2005;20(1):41–5.  https://doi.org/10.1002/hup.655.CrossRefGoogle Scholar
  11. 11.
    Waddell L, Taylor M. A new self-rating scale for detecting atypical or second-generation antipsychotic side effects. J Psychopharmacol. 2008;22(3):238–43.  https://doi.org/10.1177/0269881107087976.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Princess Alexandra HospitalBrisbaneAustralia
  2. 2.University of QueenslandBrisbaneAustralia

Personalised recommendations